The Use Of AMH for the Discrimination of Polycystic and Multicystic Ovaries in Nonhyperandrogenic Patients

Study Overview
=================
Brief Summary
-----------------
AMH is a member of the transforming growth factor family. It is produced by the granulosa cells from 36th weeks of pregnancy.Ovarian granulosa cells are the only source of the antimüllerian hormone. AMH production continues until response to exogenous FSH occurs and follicles reach 4-6 mm in diameter.The number of follicles in patients with polycystic ovaries are 2-6 times higher than normal women. Serum AMH levels are 2-3 times higher in patients with PCOS. The cause of elevated serum AMH levels in patients with PCOS is unknown. There are data showing elevated serum AMH level is due to the increase in the number of follicles 2-8 mm in diameter. Although there is no precise definition; multicystic ovarian is defined by the presence of more than six follicles 4-9 mm in diameter and mixed morphologically with PCO. PCO and multicystic ovaries are distinguished by the absence of the increase in stroma / volume.The aim of this study is to investigate whether there is a difference of serum AMH levels between patients with PCO or multicystic ovaries. A primary goal is to investigate the usability of AMH as a marker besides ultrasound for discrimination of nonhyperandrogenic patients with PCO or multicystic ovaries.

Detailed Description
-----------------
It is planned to compare the values of FSH/LH, AMH, and 75 gr OGTT between 20 patients diagnosed as PCOS according to the AES-Rotterdam criteria and 20 patients with multicystic ovarian structure but do not provide the PCOS-D3 criteria. The second purpose of this study is to investigate the mechanism that leads to the elevation of AMH in patients with PCOS, and to reveal the effects of intraovarian paracrine factors,insulin resistance and FSH /LH.

Official Title
-----------------
Elevation of AMH Resulted From Ovarian Structural Properties or Effects of Gonadotropines

Conditions
-----------------
Polycystic Ovary Syndrome

Intervention / Treatment
-----------------
* Genetic: AMH level difference between patient with PCOS and multicystic ovaries.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the ages of 15-43 >6 4-9 mm follicles in bilateral ovaries at ultrasonographic examination Increased ovarian volume (>10 ml ) Exclusion Criteria: Hormonal drug users Late onset congenital adrenal hyperplasia,androgen secreted ovarian or adrenal tumors

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 43 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ->6 4-9 mm follicles in bilateral ovaries<br>Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria | Genetic: AMH level difference between patient with PCOS and multicystic ovaries.<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-Müllerian Hormone level 0.5ng/ml -14ng/ml. | difference of serum AMH levels between patients with PCO or multicystic ovaries | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antimullarian hormone(AMH), Polycystic Ovary, Multicystic Ovary